ADIL RSI Chart
Last 7 days
4%
Last 30 days
-32.8%
Last 90 days
35.7%
Trailing 12 Months
387.5%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 29, 2023 | schuyler kevin | bought | 1,918 | 2.74 | 700 | - |
May 23, 2023 | truluck joseph | acquired | - | - | 157,500 | chief financial officer |
May 23, 2023 | stilley william b. iii | acquired | - | - | 240,800 | - |
May 23, 2023 | claiborne cary j | acquired | - | - | 420,000 | chief executive officer |
Dec 30, 2022 | stilley william b. iii | back to issuer | - | - | -166,667 | - |
Sep 20, 2022 | claiborne cary j | acquired | 31,515 | 0.4202 | 75,000 | chief executive officer |
Sep 19, 2022 | claiborne cary j | acquired | 10,735 | 0.4294 | 25,000 | chief executive officer |
Aug 18, 2022 | claiborne cary j | acquired | - | - | 1,000,000 | chief executive officer |
Feb 23, 2022 | stilley william b. iii | acquired | - | - | 250,000 | chief executive officer |
Dec 30, 2021 | newman james w. jr. | bought | 13,600 | 2.72 | 5,000 | - |
Which funds bought or sold ADIL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | added | 66.67 | 3.00 | 20.00 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -295,740 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 9.23 | -1,724 | 6,151 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -50.00 | - | - | -% |
May 14, 2024 | Qube Research & Technologies Ltd | unchanged | - | -4.00 | 11.00 | -% |
May 13, 2024 | UBS Group AG | added | 58.09 | 879 | 7,616 | -% |
May 13, 2024 | HRT FINANCIAL LP | new | - | 47,000 | 47,000 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | added | 120 | 25,000 | 68,000 | -% |
May 10, 2024 | BlackRock Inc. | unchanged | - | -4,049 | 10,160 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 37.5 | - | 15.00 | -% |
Unveiling Adial Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Adial Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Adial Pharmaceuticals Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 41.1% | 6,684 | 4,737 | 2,867 | 3,779 | 3,902 | 5,733 | 7,742 | 10,923 | 13,964 | 7,475 | 10,446 | 8,063 | 8,625 | 5,491 | 8,178 | 9,475 | 5,941 | 7,680 | 9,507 | 10,687 | 12,060 |
Current Assets | 66.8% | 5,336 | 3,199 | 1,135 | 2,047 | 2,965 | 4,780 | 6,773 | 9,940 | 12,965 | 6,462 | 7,986 | 5,590 | 6,172 | 5,136 | 8,172 | 9,469 | 5,935 | 7,673 | 9,501 | 10,681 | 12,053 |
Cash Equivalents | 77.7% | 5,025 | 2,827 | 316 | 1,218 | 2,313 | 4,002 | 5,753 | 9,157 | 12,689 | 6,062 | 7,180 | 5,210 | 5,638 | 4,401 | 7,365 | 8,624 | 4,952 | 6,777 | 8,530 | 10,254 | 11,394 |
Net PPE | - | - | - | - | - | 48.00 | 50.00 | 52.00 | 54.00 | 56.00 | 58.00 | 62.00 | 62.00 | 30.00 | - | - | - | - | - | - | - | - |
Goodwill | - | - | - | - | - | 249 | 249 | 249 | 249 | 249 | 249 | 131 | 131 | 131 | - | - | - | - | - | - | - | - |
Liabilities | -13.8% | 563 | 653 | 528 | 462 | 2,462 | 2,456 | 2,333 | 2,962 | 3,256 | 3,967 | 3,246 | 3,234 | 3,008 | 1,505 | - | - | - | - | - | - | - |
Current Liabilities | -13.8% | 563 | 653 | 528 | 462 | 1,798 | 1,791 | 1,327 | 1,867 | 2,171 | 2,722 | 1,958 | 2,213 | 2,042 | 1,505 | 1,093 | 682 | 390 | 539 | 777 | 627 | 329 |
Shareholder's Equity | 49.9% | 6,122 | 4,084 | 2,339 | 3,317 | 1,440 | 3,276 | 5,409 | 7,961 | 10,707 | 3,508 | 7,200 | 4,829 | 5,618 | 3,986 | 7,085 | 8,793 | 5,551 | 7,141 | 8,730 | 10,061 | 11,731 |
Retained Earnings | -9.4% | -75,274 | -68,797 | -66,877 | -65,492 | -66,580 | -63,674 | -60,807 | -57,698 | -53,850 | -50,943 | -45,100 | -40,794 | -36,353 | -31,519 | -28,050 | -24,714 | -22,903 | -20,626 | -18,568 | -16,852 | -14,718 |
Additional Paid-In Capital | 11.7% | 81,392 | 72,880 | 69,216 | 68,809 | 67,992 | 66,950 | 66,190 | 65,634 | 64,535 | 54,430 | 52,292 | 45,605 | 41,954 | 35,491 | 35,121 | 33,494 | 28,444 | 27,757 | 27,288 | 26,903 | 26,439 |
Shares Outstanding | 143.8% | 4,055 | 1,663 | 1,218 | 1,198 | 1,141 | 1,067 | 1,074 | 1,034 | 926 | 838 | 715 | 674 | 691 | 576 | - | - | - | - | - | - | - |
Float | - | - | - | - | 5,385 | - | - | - | 31,265 | - | - | - | 40,504 | - | - | - | 14,669 | - | - | - | 12,307 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -33.0% | -1,626 | -1,222 | -1,390 | -1,894 | -2,298 | -1,750 | -3,403 | -3,534 | -2,496 | -2,373 | -3,529 | -3,203 | -2,843 | -2,614 | -2,208 | -985 | -1,825 | -1,752 | -1,724 | -1,140 | -1,721 |
Share Based Compensation | -19.5% | 226 | 281 | 268 | 738 | 460 | 734 | 557 | 1,100 | 984 | 884 | 1,189 | 843 | 1,325 | 370 | 678 | 395 | 571 | 469 | 385 | 464 | 284 |
Cashflow From Investing | -100.0% | - | 350 | 350 | - | - | - | - | - | - | - | - | -33.73 | -286* | - | - | - | - | - | - | - | - |
Cashflow From Financing | 13.0% | 3,824 | 3,384 | 139 | 58* | 610 | - | - | 2.00 | 9,124 | 1,255 | 5,500 | 2,809 | 4,081 | - | 950 | - | - | 109* | 178* | 26* | 9,246 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating Expenses: | ||
Research and development expenses | $ 454,278 | $ 365,616 |
General and administrative expenses | 1,390,744 | 1,903,159 |
Total Operating Expenses | 1,845,022 | 2,268,775 |
Loss From Operations | (1,845,022) | (2,268,775) |
Other Income (Expense) | ||
Interest income | 22,801 | 28,892 |
Inducement expense | (4,464,427) | |
Losses from equity method investment | (189,870) | |
Other expenses | (42) | |
Total other income (expense) | (4,631,538) | 28,892 |
Loss Before Provision For Income Taxes | (6,476,560) | (2,239,883) |
Provision for income taxes | ||
Loss from Continuing Operations | (6,476,560) | (2,239,883) |
Loss from discontinued operations, net of taxes | (665,953) | |
Net Loss | $ (6,476,560) | $ (2,905,836) |
Loss per share from continuing operations, basic (in Dollars per share) | $ (2.19) | $ (2.12) |
Income (Loss) per share from discontinued operations, basic (in Dollars per share) | (0.63) | |
Net loss per share, basic (in Dollars per share) | $ (2.19) | $ (2.75) |
Weighted average shares, basic (in Shares) | 2,953,913 | 1,058,542 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 5,025,110 | $ 2,827,082 |
Prepaid research and development | 36,000 | |
Prepaid expenses and other current assets | 275,356 | 371,597 |
Total Current Assets | 5,336,466 | 3,198,679 |
Intangible assets, net | 3,772 | 3,913 |
Equity method investment | 1,344,143 | 1,534,013 |
Total Assets | 6,684,381 | 4,736,605 |
Current Liabilities: | ||
Accounts payable | 177,468 | 103,325 |
Accounts payable, related party | 24,062 | |
Accrued expenses | 375,263 | 477,747 |
Accrued expenses, related party | 10,000 | 47,942 |
Total Current Liabilities | 562,731 | 653,076 |
Total Liabilities | 562,731 | 653,076 |
Commitments and contingencies – see Note 9 | ||
Stockholders’ Equity | ||
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at March 31, 2024 and December 31, 2023 | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 4,054,861 and 1,663,421 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 4,054 | 1,663 |
Additional paid in capital | 81,392,028 | 72,879,738 |
Accumulated deficit | (75,274,432) | (68,797,872) |
Total Stockholders’ Equity | 6,121,650 | 4,083,529 |
Total Liabilities and Stockholders’ Equity | $ 6,684,381 | $ 4,736,605 |